{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,15]],"date-time":"2026-09-15T02:58:31Z","timestamp":1789441111409,"version":"build-2803163510"},"reference-count":32,"publisher":"Korean Diabetes Association","issue":"2","license":[{"start":{"date-parts":[[2025,1,6]],"date-time":"2025-01-06T00:00:00Z","timestamp":1736121600000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100004470","name":"Daewoong Pharmaceutical Co. Ltd.","doi-asserted-by":"crossref","id":[{"id":"10.13039\/501100004470","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["e-dmj.org"],"crossmark-restriction":true},"short-container-title":["Diabetes Metab J"],"published-print":{"date-parts":[[2025,3,1]]},"abstract":"<jats:p>Background: The novel sodium-glucose cotransporter-2 (SGLT2) inhibitor enavogliflozin effectively lowers glycosylated hemoglobin levels and body weights without the increased risk of serious adverse events; however, the long-term clinical benefits of enavogliflozin in terms of cardiovascular and renal outcomes have not been investigated.Methods: This study is an investigator-initiated, multicenter, randomized, pragmatic, open-label, active-controlled, non-inferiority trial. Eligible participants are adults (aged \u226519 years) with type 2 diabetes mellitus (T2DM) who have a history of, or are at risk of, cardiovascular disease. A total of 2,862 participants will be randomly assigned to receive either enavogliflozin or other SGLT2 inhibitors with proven cardiorenal benefits, such as dapagliflozin or empagliflozin. The primary endpoint is the time to the first occurrence of a composite of major adverse cardiovascular or renal events (Clinical Research Information Service registration number: KCT0009243).Conclusion: This trial will determine whether enavogliflozin is non-inferior to dapagliflozin or empagliflozin in terms of cardiorenal outcomes in patients with T2DM and cardiovascular risk factors. This study will elucidate the role of enavogliflozin in preventing vascular complications in patients with T2DM.<\/jats:p>","DOI":"10.4093\/dmj.2024.0238","type":"journal-article","created":{"date-parts":[[2025,1,6]],"date-time":"2025-01-06T01:40:30Z","timestamp":1736127630000},"page":"225-234","update-policy":"https:\/\/doi.org\/10.4093\/crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Study Design and Protocol for a Randomized Controlled Trial of Enavogliflozin to Evaluate Cardiorenal Outcomes in Type 2 Diabetes (ENVELOP)"],"prefix":"10.4093","volume":"49","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-9926-1344","authenticated-orcid":true,"given":"Nam Hoon","family":"Kim","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Soo","family":"Lim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"In-Kyung","family":"Jeong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eun-Jung","family":"Rhee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jun Sung","family":"Moon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ohk-Hyun","family":"Ryu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hyuk-Sang","family":"Kwon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jong Chul","family":"Won","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sang Soo","family":"Kim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sang Yong","family":"Kim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bon Jeong","family":"Ku","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Heung Yong","family":"Jin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7430-3675","authenticated-orcid":true,"given":"Sin Gon","family":"Kim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0542-2854","authenticated-orcid":true,"given":"Bong-Soo","family":"Cha","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"name":"on Behalf of Investigators of ENVELOP Study","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"2567","reference":[{"key":"ref1","volume-title":"","year":"2021"},{"key":"ref2","doi-asserted-by":"publisher","DOI":"10.1016\/j.diabres.2018.02.023"},{"key":"ref3","doi-asserted-by":"publisher","DOI":"10.4093\/dmj.2022.0106"},{"key":"ref4","doi-asserted-by":"publisher","DOI":"10.1210\/er.2010-0029"},{"key":"ref5","doi-asserted-by":"publisher","DOI":"10.1016\/s0140-6736(18)32590-x"},{"key":"ref6","first-page":"S158","volume-title":"9. Pharmacologic approaches to glycemic treatment: standards of care in diabetes-2024","year":"2024"},{"key":"ref7","doi-asserted-by":"publisher","DOI":"10.4093\/dmj.2023.0282"},{"key":"ref8","doi-asserted-by":"publisher","DOI":"10.3390\/pharmaceutics12030268"},{"key":"ref9","first-page":"1865","volume-title":"Efficacy and safety of enavogliflozin, a novel SGLT2 inhibitor, in Korean people with type 2 diabetes: a 24-week, multicentre, randomized, double-blind, placebo-controlled, phase III trial","author":"Kwak","year":"2023"},{"key":"ref10","doi-asserted-by":"publisher","DOI":"10.1016\/j.diabet.2023.101440"},{"key":"ref11","doi-asserted-by":"publisher","DOI":"10.4093\/dmj.2022.0315"},{"key":"ref12","doi-asserted-by":"publisher","DOI":"10.1056\/nejmra1510059"},{"key":"ref13","doi-asserted-by":"publisher","DOI":"10.1038\/nrcardio.2012.122"},{"key":"ref14","first-page":"403","volume-title":"2014 ACC\/AHA key data elements and definitions for cardiovascular endpoint events in clinical trials: a report of the American College of Cardiology\/American Heart Association task force on clinical data standards (writing committee to develop cardiovascular endpoints data standards)","author":"Hicks","year":"2015"},{"key":"ref15","doi-asserted-by":"publisher","DOI":"10.1056\/nejmoa1504720"},{"key":"ref16","doi-asserted-by":"publisher","DOI":"10.1056\/nejmoa1812389"},{"key":"ref17","doi-asserted-by":"publisher","DOI":"10.1056\/nejmoa1611925"},{"key":"ref18","doi-asserted-by":"publisher","DOI":"10.1038\/ki.2010.512"},{"key":"ref19","doi-asserted-by":"publisher","DOI":"10.1007\/s00125-016-4157-3"},{"key":"ref20","doi-asserted-by":"publisher","DOI":"10.1038\/nrneph.2016.170"},{"key":"ref21","doi-asserted-by":"publisher","DOI":"10.1186\/s12933-022-01575-9"},{"key":"ref22","doi-asserted-by":"publisher","DOI":"10.1056\/nejmoa2024816"},{"key":"ref23","doi-asserted-by":"publisher","DOI":"10.1056\/nejmoa2204233"},{"key":"ref24","first-page":"1995","volume-title":"Dapagliflozin in patients with heart failure and reduced ejection fraction","author":"McMurray","year":"2019"},{"key":"ref25","first-page":"1089","volume-title":"Dapagliflozin in heart failure with mildly reduced or preserved ejection fraction","author":"Solomon","year":"2022"},{"key":"ref26","first-page":"1413","volume-title":"Cardiovascular and renal outcomes with empagliflozin in heart failure","author":"Packer","year":"2020"},{"key":"ref27","first-page":"1451","volume-title":"Empagliflozin in heart failure with a preserved ejection fraction","author":"Anker","year":"2021"},{"key":"ref28","doi-asserted-by":"publisher","DOI":"10.1038\/ki.2010.511"},{"key":"ref29","doi-asserted-by":"publisher","DOI":"10.1111\/nyas.12098"},{"key":"ref30","doi-asserted-by":"publisher","DOI":"10.1038\/nrdp.2015.18"},{"key":"ref31","doi-asserted-by":"publisher","DOI":"10.1016\/j.semnephrol.2016.05.008"},{"key":"ref32","doi-asserted-by":"publisher","DOI":"10.1056\/nejmoa041031"}],"container-title":["Diabetes &amp; Metabolism Journal"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/e-dmj.org\/upload\/pdf\/dmj-2024-0238.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/e-dmj.org\/journal\/view.php?doi=10.4093\/dmj.2024.0238","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/e-dmj.org\/upload\/pdf\/dmj-2024-0238.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,3,11]],"date-time":"2025-03-11T07:57:19Z","timestamp":1741679839000},"score":1,"resource":{"primary":{"URL":"http:\/\/e-dmj.org\/journal\/view.php?doi=10.4093\/dmj.2024.0238"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,3,1]]},"references-count":32,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2025,3]]}},"URL":"https:\/\/doi.org\/10.4093\/dmj.2024.0238","relation":{},"ISSN":["2233-6079","2233-6087"],"issn-type":[{"value":"2233-6079","type":"print"},{"value":"2233-6087","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,3,1]]},"assertion":[{"value":"2024-05-09","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2024-08-14","order":1,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2025-01-06","order":2,"name":"published","label":"Published online","group":{"name":"publication_history","label":"Publication History"}},{"value":"2025-03-01","order":3,"name":"published","label":"Print publication","group":{"name":"publication_history","label":"Publication History"}}]}}